Premium
In vivo measurements of frequency‐dependent attenuation in tumors of the liver
Author(s) -
Dong BaoWei,
Wang Ming,
Xie Ke,
Chen MinHua
Publication year - 1994
Publication title -
journal of clinical ultrasound
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.272
H-Index - 61
eISSN - 1097-0096
pISSN - 0091-2751
DOI - 10.1002/jcu.1870220304
Subject(s) - medicine , focal nodular hyperplasia , hemangioma , adenoma , pathology , histopathology , liver tumor , hepatocellular carcinoma , in vivo , hepatocellular adenoma , attenuation , biopsy , physics , microbiology and biotechnology , optics , biology
Ultrasonic frequency‐dependent attenuation (FDA) coefficients of the liver obtained from selected regions of interest within the liver were determined in 106 individuals, 40 cases presumed normal based on medical histories and 66 with malignant tumors (hepatocellular carcinoma [HCC] or metastatic liver tumor) or benign tumors (hepatic hemangioma, hepatic adenoma, or focal nodular hyperplasia of the liver). All liver tumors were confirmed histopathologically by ultrasonically guided fine‐needle biopsy and/or operation. Mean attenuation of normal liver was 0.53 ± 0.03 dB/cm/MHz, 0.29 ± 0.05 dB/cm/MHz in hepatic hemangioma, 0.43 ± 0.05 dB/cm/MHz in HCC, and 0.41 ± 0.12 dB/cm/MHz in metastatic liver tumor. Hepatic adenoma and focal nodular hyperplasia of the liver produced higher values, averaging 0.66 ± 0.09 dB/cm/MHz. This difference between malignant and benign tumors was statistically significant. There was some correlation between the FDA for the hepatic tumor and the histopathology that merits further investigation. © 1994 John Wiley & Sons, Inc.